Add to Favourites
To login click here
LabGenius, a company that uses machine learning for antibody discovery, has secured £35 million in funding to develop their proprietary platform and progress a pipeline of multispecific antibodies towards clinical trials. The platform, known as EVA, utilises robotic automation and AI to streamline the identification of unique biotherapeutics. LabGenius aims to expand the platform’s capabilities and progress a pipeline of multispecific antibodies for treating solid tumors.